Institut Paoli-Calmettes
Marseille, 13273, France
NCT Number: NCT02526134
The purpose of this study is to estimate the rate of patients in whom a significant change in the area to be irradiated will be observed between the assessment before and after laying the evaluation of Trustees.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 2
Marseille, 13273, France
The centering of radiotherapy is done with the pre-radiation scanner for tracking the implementation of target skin markers. On this scanner, it is often difficult for the radiation therapist to pinpoint the target volume. To improve the definition of the target volume, image fusion techniques with other imaging tests were developed.
To improve the pre-radiotherapy identification, setting up markers echo-endoscopy has been described without major complications. The impact on targeting radiotherapy was mainly described for the prostate.
The marking of digestive tumors was described by the establishment of Trustees, radiopaque markers in the lymph nodes, esophagus, stomach, pancreas, and bile ducts.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From inclusion to 12 months follow up
Observing whether there is a significant variation of the area to be irradiated
Time frame: From inclusion to 12 months follow up
Safety and security are measured by statistical analysis (numbers and percentage for qualitative variables and by average, median, standard deviations and extreme values for quantitative variables.
Institut Paoli-Calmettes
Other
Acronym: FIDUCOR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04476082
Bile Duct Cancer, Bile Duct Diseases
Greifswald, Germany
View Trial DetailsNCT05266300
Adverse Drug Event, Bile Duct Cancer
Odense, Region Syddanmark, Denmark
View Trial DetailsNCT06277921
Digestive System Diseases, Digestive System Neoplasms
Minsk, Belarus
View Trial DetailsNCT03212469
Carcinoma, Carcinoma, Squamous Cell
Villejuif, Val De Marne, France
View Trial Details